폴리오 백신 시장 보고서 : 동향, 예측, 경쟁 분석(-2031년)

The future of the global poliomyelitis vaccine market looks promising with opportunities in the VAPP, VDPV markets. The global poliomyelitis vaccine market is expected to grow with a CAGR of 2.3% from 2025 to 2031. The major drivers for this market are the growing awareness about immunization and the need for routine vaccinations, and the strong funding and support from governments and organizations.

• Lucintel forecasts that, within the type category, the oral poliomyelitis vaccine is expected to witness higher growth over the forecast period due to the growing demand for easy-to-administer and needle-free vaccination options, which is boosting oral polio vaccine use.
• Within the application category, VDPV is expected to witness higher growth due to rising concerns over VDPV outbreaks, which are driving demand for targeted vaccination strategies.
• In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Poliomyelitis Vaccine Market

The global poliomyelitis vaccine market is constantly changing as there are new challenges and new opportunities when it comes to vaccine formulation, distribution, and immunization plans. The recent trends are targeting the perpetual efforts to eradicate polio, widening the scope of available vaccines in neglected areas, and addressing the problems of outbreaks of vaccine-derived poliovirus. Below are five emerging trends that are persistent in the shaping of the global poliomyelitis vaccine market.

• Increasing automation of the inactivated polio vaccine: As the vaccine-derived poliovirus (VDPV) index cases have raised alarm bells around the world, most countries are transitioning from oral polio vaccine (OPV) to IPV. IPV also removes the VDPV risk but preserves immunity, which remains critical in ensuring that polio eradication is achieved. This transition is most relevant in regions with poor immunization rates and weak healthcare infrastructure. The world market for IPV is expanding owing to its ability to provide safe and long-term immunity against polio with minimal chances of another outbreak.
• Growing emphasis on surveillance and monitoring: With the goal of eradicating polio from the entire globe, there is an increasing need to strengthen the surveillance system to detect and monitor poliovirus transmission. Surveillance includes not only the genetic makeup of the virus but also improvements in the reporting of events and tracking vaccination coverage. Surveillance is vital even for countries that have already been polio-free for years but pose risks due to low vaccination coverage or migration patterns. These enhancements are critical for the early detection of outbreaks and limiting potential spread through early interventions.
• Vaccination deliveries linked with other national strategies: Some countries are using this strategy to improve the coverage of polio vaccination while at the same time reducing operational expenditures. Such integrated approaches target increased coverage by interspersing polio vaccinations with measles or hepatitis B and improving the availability of various routine vaccines to children, which would otherwise go unvaccinated. This is becoming a more crucial trend in low-income and hard-to-reach areas where distances to healthcare facilities are vast. Integrating children into available programs also improves the general immunization system and the public health systems.
• Development of new types of polio vaccines: Novel combination vaccines and improved formulations are under development. These vaccines are expected to improve the immune response, ease vaccine delivery, and improve stability features required for transport and storage. New adjuvants or delivery systems, as well as combined vaccines, e.g., polio with other vaccines administered to children, are being investigated. Such innovations may offer better options, especially in areas that have logistical constraints or where there are new patterns of outbreaks.
• Private sector and public-private partnerships: Participation of the private sector in the global polio vaccination campaign has risen, with pharmaceutical companies investing towards vaccine manufacturing, marketing, and research. Public-private partnerships are effective in complementing polio eradication strategies, particularly in resource-constrained settings. Such collaborations assist in developing vaccine stocks and pricing for lower- and middle-income countries, thus enhancing global polio eradication efforts.

As the world moves rapidly towards the goal of eradicating polio, trends such as the usage of IPV, improved issues on surveillance, or the streamlining of vaccines with immunization programs are strong emerging trends in the global poliomyelitis vaccine market. These trends are enhancing the availability of vaccines, increasing the safety of polio vaccines, and improving the efficiency of administration worldwide. And, as in the case of public-private partnerships, new types of vaccines and their development are helping to overcome logistical and financial constraints on wide-scale immunization campaigns.

Recent Developments in the Poliomyelitis Vaccine Market

The latest changes in the global poliomyelitis vaccine market are purposeful, as they draw attention to factors such as the introduction of an IPV booster dose, production innovations, distribution innovations, and international cooperation, which are crucial for the global success of the polio eradication campaign. Progress in the development of polio vaccination strategies contributes to the targeted end goal, which is the global eradication of polio and elimination of vaccine-derived strains, increasing vaccination coverage, and including non-represented people. Below are five key developments shaping the future of the global poliomyelitis vaccine market.

• Global move from OPV usage towards IPV: The global movement from the use of oral polio vaccine (OPV) to inactivated polio vaccine (IPV) is one of the major changes in the poliomyelitis vaccine market. With IPV, countries do not have the risk of vaccine-associated poliovirus (VAP), which was a challenge with OPV in some settings. This change is advocated by WHO and other health organizations to enhance immunity safely. IPV doses are incorporated into national immunization schedules to keep the objectives of the global eradication campaign on track.
• IPV use improved in routine immunization schedules: Countries like India, China, and others have already incorporated IPV into their routine vaccination programs, aiding in the fight against polio. The use of IPV with OPV during the last stages of eradication has helped maintain population immunity without heightening the threat of VDPV outbreaks. The two approaches supplement each other and help enhance vaccination campaigns, preventing re-emergence of polio.
• Enhanced systems of surveillance: The transmission of polio has been effectively controlled through stricter surveillance systems. Polio virus strain genetic sequencing, improved reporting systems, and real-time information have become indispensable for early detection of outbreaks. Such advancements allow for rapid response measures, especially in countries where outbreaks have occurred, ensuring that immunization takes place as quickly as possible. This guarantees that no new cases of polio are missed and strengthens the final push to end the disease.
• Greater contributions worldwide for polio eradication efforts: Significant funding from global health organizations, governments, and private entities has been received, notably supporting projects like the Global Polio Eradication Initiative (GPEI). These investments facilitate vaccine marketing campaigns and administration, even in rare and conflict-hit areas. Reinforcing health infrastructure and financial backing has significantly contributed to the success of vaccination programs and kept polio as a focus in global health.
• Public-private partnerships for accessible vaccines: Companies like GSK, Sanofi, and others working with international health organizations have played a key role by making polio vaccines available and affordable in many low-income and underserved areas. Efforts aim to make vaccine access possible in more countries by overcoming barriers such as high costs, logistical issues, and inadequate healthcare provision. Such collaborations help develop vaccine stocks, improve distribution, and expand global vaccine manufacturing activities.

Recent developments in the global poliomyelitis vaccine market highlight the importance of transitions, surveillance, funding, and collaborations in the fight against polio. Support for IPV introduction, improved surveillance, and public-private partnerships have enhanced the global push for vaccination. These efforts, combined with addressing vaccine-related challenges and outbreaks, are bringing the world closer to the elimination of polio. The market now focuses on ensuring that polio remains eradicated through sustained immunization and surveillance programs worldwide.

Strategic Growth Opportunities in the Poliomyelitis Vaccine Market

The world's poliomyelitis vaccine market is experiencing acceleration in development owing to challenges posed to polio eradication: mass vaccinations, improvements in vaccine development and dissemination, global cooperation, etc. Now that polio has been eradicated in most places, the challenge is to eliminate this disease entirely and focus on new challenges. The market is still developing and offers possibilities for new strategies in producing, distributing, and monitoring vaccines. In particular, with most countries switching from the oral form of the polio vaccine to the inactivated type, here are five growth opportunities that will cut across sectors in the poliomyelitis vaccine market.

• Increasing usage of IPV within routine immunization schedules: The transition from OPV to IPV brings potential for increased revenue. IPV offers enhanced safety as residual VDPV is absent. Continued use of IPV in countries that have achieved polio-free status will help protect against resurgence. This change necessitates increased capacity in vaccine manufacturing, cold chain logistics, and regulatory frameworks, providing growth avenues for manufacturers and health organizations.
• The use of combination vaccines to eradicate polio circulation: Including polio vaccines in DTP (diphtheria, tetanus, pertussis) vaccines enhances the market. Combining polio vaccination with wider immunization activities lowers operational costs and raises coverage. This strategy stimulates demand for combination vaccines, which is cost-effective for manufacturers and health agencies aiming to immunize every child.
• Opportunities and constraints regarding polio surveillance and monitoring technologies: Advanced surveillance technology is critical for global eradication, offering opportunities in genomic surveillance, diagnostic technologies, handheld health devices, and real-time reporting systems. Reinforcing surveillance networks is especially important in weak health system areas or where polio is still endemic. This creates opportunities for diagnostic testing services and data analysis.
• Polio vaccine manufacturing and supply chain improvements: The increasing demand for vaccines creates growth opportunities for manufacturing and distribution. Improving vaccine formulation and supply chain management is critical for consistent supply, especially in remote or conflict-affected regions. Collaboration between public health agencies and private companies will enhance market profitability and effectiveness.
• Public-private partnerships for polio eradication: PPPs have become effective in increasing vaccination coverage in underserved regions. These partnerships enable increased funding, resource sharing, and expertise, helping to overcome geographical and financial barriers. Securing investments through these partnerships enhances rapid deployment, infrastructure development, and manufacturing expansion.

The scenario of the poliomyelitis vaccine market globally looks favorable, with several growth opportunities such as vaccine proliferation, collaboration with other vaccine programs, technology integration for surveillance, improved manufacturing processes, and public-private partnerships. These opportunities support efforts to achieve polio eradication and sustained immunity in the post-eradication period. Synergistic actions between manufacturers, international health bodies, and governments are essential for enhancing vaccination, supply chain management, and surveillance.

Poliomyelitis Vaccine Market Driver and Challenges

There are many factors affecting the global market of poliomyelitis vaccines, including technological innovations, economic factors, and regulations. These factors influence vaccine purchase, vaccination processes, and the effectiveness of global eradication efforts. However, there are setbacks such as vaccine-derived poliovirus outbreaks, logistical issues, and regional heterogeneity in immunization, which remain challenges. It is important to assess and understand the factors driving and restraining the poliomyelitis vaccine market to succeed.

The factors responsible for driving the Poliomyelitis Vaccine market include:

1. Global campaigns for polio eradication: Led by the Global Polio Eradication Initiative (GPEI), involving WHO, UNICEF, and the Rotary Foundation, supported by substantial funding and political will, improving vaccination levels and supply, and establishing demand for OPV and IPV.

2. Shift toward IPV: The transition from OPV to IPV in immunization programs, especially in polio-free countries, to address VDPV concerns, increasing demand for IPV vaccines.

3. Technological advancements in vaccine production: Innovations such as recombinant DNA, adjuvants, and new formulations reduce costs and increase vaccine availability, especially in poor and conflict-affected regions.

4. Enhanced vaccine availability in developing economies: Initiatives like GAVI make vaccines accessible at reasonable prices, helping restore coverage in endemic areas.

5. Global networking and financial support: International funding and sponsorship support ongoing vaccination, research, and health system strengthening.

Challenges include:

1. Vaccine-derived poliovirus (VDPV): Outbreaks of VDPV, especially with OPV, pose a major obstacle. WHO advocates for IPV to eliminate this risk, but high costs and logistical issues hinder widespread adoption.

2. Logistical challenges: Distribution issues in rural and conflict zones, cold chain problems, wastage, and transportation hurdles.

3. Political conditions and conflict zones: Ongoing violence and conflict, especially in Afghanistan and Pakistan, hinder vaccination efforts.

International cooperation, improved mechanisms, and persistent efforts are necessary to eradicate poliomyelitis globally. Addressing challenges like VDPV, logistics, and socio-political issues is crucial for effective immunization programs.

List of Poliomyelitis Vaccine Companies

Companies in the market compete based on product quality. Major players focus on expanding manufacturing, R&D, infrastructure, and leveraging integration across the value chain. These strategies help cater to increasing demand, develop innovative products, reduce costs, and expand customer bases. Some of the companies profiled include:

• GSK
• Sanofi-Pasteur
• Merck
• Crucell
• China National Biotech Group

Poliomyelitis Vaccine Market by Segment

The study includes a forecast for the global poliomyelitis vaccine market by type, application, and region.

Poliomyelitis Vaccine Market by Type [Value from 2019 to 2031]:

• Poliomyelitis Vaccine I
• Poliomyelitis Vaccine II
• Poliomyelitis Vaccine III
• Oral Poliomyelitis Vaccine

Poliomyelitis Vaccine Market by Application [Value from 2019 to 2031]:

• VAPP
• VDPV

Poliomyelitis Vaccine Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Poliomyelitis Vaccine Market

The global poliomyelitis vaccine market has been a concern for numerous decades. The highly contagious disease, if left unmanaged, can lead to death or paralysis. Efforts to eliminate the disease have been mostly successful owing to advancements in polio vaccines. In countries such as the USA, China, Germany, India, and Japan, recent advancements focus on expanding vaccine distribution, managing outbreaks, and providing assistance with the last phase of elimination. Improvements in diffusion methods and timing, localized educational programs, and closer collaboration between global health agencies are expected to advance vaccination efforts in these areas.

• United States: Despite being at the forefront of polio vaccination and eradication efforts, occasional outbreaks from vaccine strains occur due to OPV. Prevention strategies include promoting IPV use. The CDC has expanded surveillance systems, ensured robust vaccination programs, and supports global eradication efforts. Maintaining polio-free certification through continuous investments and immunity is paramount.
• China: China has made significant progress in combating poliomyelitis, switching from OPV to IPV in 2016. Efforts include enhancing immunization systems, routine vaccination coverage, and vaccine supply chain management. China collaborates with WHO and other organizations, though challenges remain in large rural populations and migration.
• Germany: Germany remains a key player in global polio eradication, vaccinating with IPV only, maintaining high coverage, and participating in campaigns like GPEI. The country emphasizes awareness among migrants to ensure access to vaccination. Its strong healthcare system supports these efforts.
• India: India was declared polio-free in 2014 after decades of vaccination campaigns. Current efforts focus on maintaining this status and increasing immunization coverage, especially among marginalized and rural communities, with active government involvement.
• Japan: Japan has maintained excellent polio vaccination coverage for decades, employing IPV-only strategies. It supports international campaigns and has strengthened its health system to prevent reintroduction, serving as a leader in global health.

Features of the Global Poliomyelitis Vaccine Market

• Market Size Estimates: Estimation of market size in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecasts (2025 to 2031) by segments and regions.
• Segmentation Analysis: Market size by type, application, and region in dollar value.
• Regional Analysis: Breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities across types, applications, and regions.
• Strategic Analysis: Includes M&A, new product development, and competitive landscape.

Industry competitiveness based on Porter's Five Forces model.

This report answers the following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the poliomyelitis vaccine market by type (poliomyelitis vaccine I, II, III, and oral poliomyelitis vaccine), application (VAPP and VDPV), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Poliomyelitis Vaccine Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Poliomyelitis Vaccine I: Trends and Forecast (2019-2031)
• 4.4 Poliomyelitis Vaccine II: Trends and Forecast (2019-2031)
• 4.5 Poliomyelitis Vaccine III: Trends and Forecast (2019-2031)
• 4.6 Oral Poliomyelitis Vaccine: Trends and Forecast (2019-2031)

5. Global Poliomyelitis Vaccine Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 VAPP: Trends and Forecast (2019-2031)
• 5.4 VDPV: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Poliomyelitis Vaccine Market by Region

7. North American Poliomyelitis Vaccine Market

• 7.1 Overview
• 7.2 North American Poliomyelitis Vaccine Market by Type
• 7.3 North American Poliomyelitis Vaccine Market by Application
• 7.4 United States Poliomyelitis Vaccine Market
• 7.5 Mexican Poliomyelitis Vaccine Market
• 7.6 Canadian Poliomyelitis Vaccine Market

8. European Poliomyelitis Vaccine Market

• 8.1 Overview
• 8.2 European Poliomyelitis Vaccine Market by Type
• 8.3 European Poliomyelitis Vaccine Market by Application
• 8.4 German Poliomyelitis Vaccine Market
• 8.5 French Poliomyelitis Vaccine Market
• 8.6 Spanish Poliomyelitis Vaccine Market
• 8.7 Italian Poliomyelitis Vaccine Market
• 8.8 United Kingdom Poliomyelitis Vaccine Market

9. APAC Poliomyelitis Vaccine Market

• 9.1 Overview
• 9.2 APAC Poliomyelitis Vaccine Market by Type
• 9.3 APAC Poliomyelitis Vaccine Market by Application
• 9.4 Japanese Poliomyelitis Vaccine Market
• 9.5 Indian Poliomyelitis Vaccine Market
• 9.6 Chinese Poliomyelitis Vaccine Market
• 9.7 South Korean Poliomyelitis Vaccine Market
• 9.8 Indonesian Poliomyelitis Vaccine Market

10. ROW Poliomyelitis Vaccine Market

• 10.1 Overview
• 10.2 ROW Poliomyelitis Vaccine Market by Type
• 10.3 ROW Poliomyelitis Vaccine Market by Application
• 10.4 Middle Eastern Poliomyelitis Vaccine Market
• 10.5 South American Poliomyelitis Vaccine Market
• 10.6 African Poliomyelitis Vaccine Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Poliomyelitis Vaccine Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 GSK
  • Company Overview
  • Poliomyelitis Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Sanofi-Pasteur
  • Company Overview
  • Poliomyelitis Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Merck
  • Company Overview
  • Poliomyelitis Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Crucell
  • Company Overview
  • Poliomyelitis Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 China National Biotech Group
  • Company Overview
  • Poliomyelitis Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us